Illumina inks multi-year supply agreement with LabCorp

Illumina, Inc. (NASDAQ:ILMN) today announced it has entered into a multi-year supply agreement with Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH). The agreement gives LabCorp expanded rights to use Illumina next-generation sequencing (NGS) and microarray equipment and supplies to develop, validate and introduce laboratory-developed tests to clinicians in the United States and Canada.

Under the terms of the agreement, LabCorp will be able to purchase a broader range of Illumina products for the development of new diagnostic tools in multiple specialties, including genetic testing, oncology, transplant medicine and forensics, in addition to other applications. LabCorp is currently using the technology in connection with new human leukocyte antigen (HLA) tests that it plans to introduce this year.

"The Illumina next-generation sequencing platform gives LabCorp the flexibility to develop a wide range of molecular tests," said Dr. Mark Brecher, LabCorp's Chief Medical Officer. "The HLA typing assays we are developing on Illumina's family of NGS platforms will provide physicians with the ability to more accurately match bone marrow donors to recipients."

"We are excited to support LabCorp's ability to offer more NGS-based tests such as its HLA offering," said Nicholas J. Naclerio, Illumina's Senior Vice President of Corporate & Venture Development. "Illumina is committed to making NGS broadly available for clinical laboratory testing, and this agreement with LabCorp significantly expands the number of clinicians and patients who will have access to improved diagnostic tools and information."

SOURC EIllumina, Inc.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Illumina, Inc.. (2018, July 27). Illumina inks multi-year supply agreement with LabCorp. News-Medical. Retrieved on February 27, 2024 from

  • MLA

    Illumina, Inc.. "Illumina inks multi-year supply agreement with LabCorp". News-Medical. 27 February 2024. <>.

  • Chicago

    Illumina, Inc.. "Illumina inks multi-year supply agreement with LabCorp". News-Medical. (accessed February 27, 2024).

  • Harvard

    Illumina, Inc.. 2018. Illumina inks multi-year supply agreement with LabCorp. News-Medical, viewed 27 February 2024,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
H3Africa Initiative selects Illumina to develop new array for genome-wide association studies